Rheumatic complications in cancer patients treated with immune checkpoint inhibitors
Immune checkpoint inhibitors (ICIs) have revolutionized anticancer therapy due to their long-term clinical benefits and immune boosting mechanisms. However, despite their consistent therapeutic effects, the use of ICIs is associated with a spectrum of adverse events due to their autoimmune and auto-...
Main Authors: | Kyung-Ann Lee, Hae-Rim Kim, So Young Yoon |
---|---|
Format: | Article |
Language: | English |
Published: |
The Korean Association of Internal Medicine
2019-11-01
|
Series: | The Korean Journal of Internal Medicine |
Subjects: | |
Online Access: | http://www.kjim.org/upload/pdf/kjim-2019-060.pdf |
Similar Items
-
Rheumatic Manifestations in Patients Treated with Immune Checkpoint Inhibitors
by: Konstantinos Melissaropoulos, et al.
Published: (2020-05-01) -
Immune Checkpoint Inhibitor-Induced Myositis/Myocarditis with Myasthenia Gravis-like Misleading Presentation: A Case Series in Intensive Care Unit
by: François Deharo, et al.
Published: (2022-09-01) -
Paraneoplastic Neurological Syndromes and Beyond Emerging With the Introduction of Immune Checkpoint Inhibitor Cancer Immunotherapy
by: Cristina Valencia-Sanchez, et al.
Published: (2021-04-01) -
Severe combined cardiac and neuromuscular toxicity from immune checkpoint blockade: an institutional case series
by: Puja Arora, et al.
Published: (2020-09-01) -
Neuromuscular Weakness Syndromes from Immune Checkpoint Inhibitors: A Case Series and Literature Review
by: Ahmad Daher, et al.
Published: (2019-05-01)